Skip to content

15th HIV Resistance Workshop: can new Tibotec NNRTI overcome cross-class resistance?

FDA approves first three-drug fixed-dose tablet for PEPFAR use

Kaletra receives EU marketing approval; developing countries registration 'moving forward'

Warning issued over bleeding within the skull in patients taking tipranavir

Darunavir (TMC114) approved for use in treatment-experienced patients in US

Tipranavir study halted in treatment-naive

Generic version of abacavir approved for use by PEPFAR programmes

Tablet version of Kaletra receives European green light; MSF calls for fast registration in Africa

Next generation NRTI, DFC (Reverset) discontinued due to safety concerns